"Geva says the company, which specializes in software and devices that aim to reduce inefficiencies in health care delivery, will remain listed on the Australian Stock Exchange, but will begin trading on the major US exchange in early 2019."
I will be pleasantly surprised if it list in Q1. Personally, I expect it will be Q2..
FDA OTC prizma will probably come Q1
Yacov talks about acquisitions and that could come in the form of more IDTF for USA to cope with demand for patch and for GMP
GMV Price at posting:
36.5¢ Sentiment: None Disclosure: Not Held
